Fernandez O, Tintore M, Saiz A, Calles-Hernandez M C, Comabella M, Ramio-Torrenta Ll, Oterino A, Izquierdo G, Tellez N, Garcia-Merino J A, Brieva Ll, Arnal-Garcia C, Aladro Y, Mendibe-Bilbao M M, Meca-Lallana J E, Romero-Pinel L, Ginestal R, Martinez-Gines M L, Arroyo R, Rodriguez-Antiguedad A
Hospital Regional Universitario de Malaga, Malaga, Espana.
Hospitals Vall d'Hebron, 08035 Barcelona, Espana.
Rev Neurol. 2018 Jul 1;67(1):15-27.
The Post-ECTRIMS Meeting is an emblematic event in the field of multiple sclerosis in Spain. Its chief aim is bring together the country's leading specialist neurologists to analyse the main advances made in multiple sclerosis and to review the most important topics addressed at the ECTRIMS Congress. The tenth Post-ECTRIMS Meeting was held in November 2017. Over the years this event has firmly established itself as an important meeting point where experts from all over the country get together to foster communication, establish synergies and promote and enhance research ultimately aimed at improving the prognosis and quality of life of patients with multiple sclerosis. This first part reports on the publication of the new European and American clinical guidelines on the use of disease-modifying treatments and the new diagnostic criteria. It also discusses the strategies for following up patients treated with disease-modifying therapies, reviews cerebral atrophy and biomarkers of neurodegeneration and neuroinflammation, and analyses the role of neuroglia in pathogenesis and treatment. The study examines the natural history of the disease, with the evidence provided by registers, and we anticipate the future thanks to the progress being made in genetics and immunology.
ECTRIMS会后会议是西班牙多发性硬化症领域的标志性活动。其主要目的是召集该国顶尖的神经科专家,分析多发性硬化症取得的主要进展,并回顾ECTRIMS大会上讨论的最重要议题。第十届ECTRIMS会后会议于2017年11月举行。多年来,该活动已牢固确立为一个重要的汇聚点,来自全国各地的专家齐聚于此,促进交流、建立协同合作关系,并推动和加强研究,最终目标是改善多发性硬化症患者的预后和生活质量。第一部分报告了关于疾病修饰治疗使用的新欧美临床指南及新诊断标准的发布情况。还讨论了对接受疾病修饰疗法治疗的患者进行随访的策略,回顾了脑萎缩以及神经退行性变和神经炎症的生物标志物,并分析了神经胶质细胞在发病机制和治疗中的作用。该研究借助登记数据提供的证据审视了疾病的自然史,并基于遗传学和免疫学的进展展望未来。